Fusion Protein of an Anti-CD20 Antibody Fab Fragment and Lidamycin, a Method for Preparing the Same, and the Use Thereof
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Aug 2, 2012
app pub date -
Jul 27, 2010
filing date -
Jul 28, 2009
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
The present invention relates to an anticancer drug, an energized fusion protein Anti-CD20(Fab)-LDM of lidamycin, a gene encoding the same; and further relates to a method for construction of the energized fusion protein in a genetic engineering manner and the use of the energized fusion protein. The applicant provides an anti-tumor drug with a good targeting ability by providing the energized fusion protein.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully